287 related articles for article (PubMed ID: 31818069)
61. [Clinical characteristics of high-grade B-cell lymphomas with rearrangement of MYC, bcl-6 and bcl-2].
Gong JY; Zhang YZ; Zhang JD; Zhang W; Li JQ; Ru K; Liu EB
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):14-18. PubMed ID: 29325245
[No Abstract] [Full Text] [Related]
62. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
[TBL] [Abstract][Full Text] [Related]
63. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
64. [Significance and application of c-myc in diffuse large B-cell lymphoma].
Huang WT; Lü N; Guo L
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
[No Abstract] [Full Text] [Related]
65. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
66. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
Davies A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):284-294. PubMed ID: 29222268
[TBL] [Abstract][Full Text] [Related]
67. Primary cardiac large B cell lymphoma.
Arun Kumar S; Mishra R; Malempati SC; Bindal P
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38151268
[TBL] [Abstract][Full Text] [Related]
68. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.
Clark Schneider KM; Banks PM; Collie AM; Lanigan CP; Manilich E; Durkin LM; Hill BT; Hsi ED
Leuk Lymphoma; 2016 Jul; 57(7):1640-8. PubMed ID: 26421520
[TBL] [Abstract][Full Text] [Related]
69. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
[TBL] [Abstract][Full Text] [Related]
70. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
[TBL] [Abstract][Full Text] [Related]
71. CD5-positive follicular lymphoma: a case report and literature review.
Sekiguchi Y; Imai H; Wakabayashi M; Sawada T; Ichikawa K; Komatsu N; Noguchi M
Intern Med; 2011; 50(8):899-904. PubMed ID: 21498939
[TBL] [Abstract][Full Text] [Related]
72. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells.
Jovanović MP; Jaković L; Bogdanović A; Marković O; Martinović VC; Mihaljević B
Vojnosanit Pregl; 2009 Sep; 66(9):738-43. PubMed ID: 19877554
[TBL] [Abstract][Full Text] [Related]
73. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Coiffier B; Sarkozy C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):366-378. PubMed ID: 27913503
[TBL] [Abstract][Full Text] [Related]
74. [Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases].
Li D; Mi C; Zhao Y; Wang YL; Ma Y; Li YY; Xiang MH
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):461-5. PubMed ID: 17845759
[TBL] [Abstract][Full Text] [Related]
75. Double-Hit Large B Cell Lymphoma.
Khelfa Y; Lebowicz Y; Jamil MO
Curr Oncol Rep; 2017 Sep; 19(11):74. PubMed ID: 28952038
[TBL] [Abstract][Full Text] [Related]
76. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
77. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
[No Abstract] [Full Text] [Related]
78. [Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].
Shen X; Zhou LT; Li AQ; Yi HM; Ouyang BS; Xu HM; Xie JL; Gu YJ; Zhang L; Dong L
Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):120-125. PubMed ID: 35152630
[No Abstract] [Full Text] [Related]
79. A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass.
Yousif P; Kotecha A; Thakur A; Ismail HM
Am J Case Rep; 2019 Dec; 20():1821-1825. PubMed ID: 31809493
[TBL] [Abstract][Full Text] [Related]
80. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.
Suzuki M; Muroi A; Nojima M; Numata A; Takasaki H; Sakai R; Yokose T; Miyagi Y; Koshikawa N
Proteomics Clin Appl; 2020 Jan; 14(1):e1900091. PubMed ID: 31721454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
